DE60305438T2 - Lyophilisierte pharmazeutische zusammensetzung von propofol - Google Patents
Lyophilisierte pharmazeutische zusammensetzung von propofol Download PDFInfo
- Publication number
- DE60305438T2 DE60305438T2 DE60305438T DE60305438T DE60305438T2 DE 60305438 T2 DE60305438 T2 DE 60305438T2 DE 60305438 T DE60305438 T DE 60305438T DE 60305438 T DE60305438 T DE 60305438T DE 60305438 T2 DE60305438 T2 DE 60305438T2
- Authority
- DE
- Germany
- Prior art keywords
- propofol
- cyclodextrin
- pharmaceutical composition
- freeze
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 229960004134 propofol Drugs 0.000 title claims abstract description 75
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 56
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 12
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 36
- 238000007710 freezing Methods 0.000 claims description 10
- 230000008014 freezing Effects 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims 2
- 239000001272 nitrous oxide Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
- 239000000243 solution Substances 0.000 description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 238000003756 stirring Methods 0.000 description 12
- 229940097362 cyclodextrins Drugs 0.000 description 7
- 229910001873 dinitrogen Inorganic materials 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 5
- 229960000991 ketoprofen Drugs 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000001116 FEMA 4028 Substances 0.000 description 4
- 229960004853 betadex Drugs 0.000 description 4
- -1 cyclic oligosaccharides Chemical class 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000002960 lipid emulsion Substances 0.000 description 4
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 1
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960003305 alfaxalone Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000012844 infrared spectroscopy analysis Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200200929 | 2002-02-01 | ||
| ZA200200929 | 2002-02-01 | ||
| US40163302P | 2002-08-06 | 2002-08-06 | |
| US401633P | 2002-08-06 | ||
| PCT/IB2003/000266 WO2003063824A2 (en) | 2002-02-01 | 2003-01-29 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60305438D1 DE60305438D1 (de) | 2006-06-29 |
| DE60305438T2 true DE60305438T2 (de) | 2006-12-21 |
Family
ID=27669352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60305438T Expired - Lifetime DE60305438T2 (de) | 2002-02-01 | 2003-01-29 | Lyophilisierte pharmazeutische zusammensetzung von propofol |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050239746A1 (enExample) |
| EP (1) | EP1469886B8 (enExample) |
| JP (1) | JP2005522422A (enExample) |
| CN (1) | CN1625414A (enExample) |
| AT (1) | ATE326985T1 (enExample) |
| AU (1) | AU2003205930B2 (enExample) |
| BR (1) | BR0307518A (enExample) |
| CA (1) | CA2474710A1 (enExample) |
| DE (1) | DE60305438T2 (enExample) |
| MX (1) | MXPA04007328A (enExample) |
| NZ (1) | NZ534598A (enExample) |
| WO (1) | WO2003063824A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004025151D1 (de) * | 2004-03-10 | 2010-03-04 | Shimoda Biotech Pty Ltd | Stabile injizierbare Diclofenac- Zubereitungen |
| US20060198891A1 (en) | 2004-11-29 | 2006-09-07 | Francois Ravenelle | Solid formulations of liquid biologically active agents |
| CN101155580A (zh) | 2005-04-13 | 2008-04-02 | 株式会社大塚制药工场 | 含异丙酚的脂肪乳剂 |
| JP2009504634A (ja) * | 2005-08-12 | 2009-02-05 | ブハラット セルムズ アンド ヴァクシンズ リミテッド | プロポフォールを含む水性麻酔剤組成物 |
| EP2522343A1 (en) | 2006-03-28 | 2012-11-14 | Javelin Pharmaceuticals, Inc. | Formulations of Low Dose Diclofenac and Beta-Cyclodextrin |
| EP2106786A1 (de) * | 2008-04-04 | 2009-10-07 | Roewer, Norbert, Univ.-Prof. Dr. med. | Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin |
| EP2484350B1 (de) * | 2011-02-04 | 2016-04-20 | Roewer, Norbert, Univ.-Prof. Dr. med. | Pharmazeutische Zubereitung, enthaltend einen Komplex eines Propofolsalzes mit einem Cyclodextrin |
| ES2784629T3 (es) * | 2011-11-29 | 2020-09-29 | Jurox Pty Ltd | Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona |
| CN103172658B (zh) * | 2011-12-26 | 2016-01-20 | 宜昌人福药业有限责任公司 | 一种适合药用的前体药物晶型、制备方法及药用组合物 |
| US9925274B2 (en) | 2012-11-15 | 2018-03-27 | Sapiotec Gmbh | Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient |
| JP6234475B2 (ja) | 2012-12-11 | 2017-11-22 | ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ | メラノーマ細胞に対抗するためのデルフィニジン |
| EP2913050A1 (de) * | 2014-02-28 | 2015-09-02 | SapioTec GmbH | Verfahren zur Herstellung eines Flurankomplexes |
| CN104523591B (zh) * | 2014-12-19 | 2019-01-18 | 西安力邦肇新生物科技有限公司 | 无致敏性、无痛丙泊酚脂肪微乳冻干制剂配方和制备方法 |
| CN111529695A (zh) * | 2020-04-30 | 2020-08-14 | 首都医科大学附属北京康复医院（北京工人疗养院） | 一种环糊精可溶性ace2及其制备方法和应用 |
| KR102975307B1 (ko) * | 2020-10-30 | 2026-06-10 | 현대자동차주식회사 | 차아염소산수를 이용한 차량용 살균장치 및 그 제어방법 |
| FR3117337B1 (fr) | 2020-12-10 | 2023-04-28 | Centre Hospitalier Univ De Lille | Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable |
| CN118715017A (zh) * | 2022-02-18 | 2024-09-27 | 贝伦治疗公益公司 | 用2-羟基丙基-β-环糊精治疗高甘油三酯血症 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA828580B (en) * | 1981-12-23 | 1983-10-26 | Schering Corp | Interferon formulations |
| ZA962214B (en) * | 1995-04-10 | 1996-10-07 | Farmarc Nederland Bv | Pharmaceutical composition |
| AU5774796A (en) * | 1995-06-13 | 1997-01-09 | Dyer, Alison Margaret | Pharmaceutical compositions containing lornoxicam and cyclod extrin |
| DE69721235T2 (de) * | 1996-02-19 | 2004-02-05 | Amersham Health As | Verbesserungen an (oder im bezug auf) kontrastmittel |
| US6407278B2 (en) * | 1998-11-16 | 2002-06-18 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and methods for the preparation and use of the same |
| US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| DE60017194T2 (de) * | 1999-10-29 | 2005-12-22 | Merck & Co., Inc. | Verfahren zur herstellung von carbapenem-antibiotika zubereitungen |
| IN187686B (enExample) * | 2000-06-21 | 2002-06-08 | Bharat Serums & Vaccines Ltd | |
| EP1383445A4 (en) * | 2001-03-20 | 2005-04-13 | Cydex Inc | FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN |
-
2003
- 2003-01-29 WO PCT/IB2003/000266 patent/WO2003063824A2/en not_active Ceased
- 2003-01-29 US US10/503,067 patent/US20050239746A1/en not_active Abandoned
- 2003-01-29 MX MXPA04007328A patent/MXPA04007328A/es unknown
- 2003-01-29 JP JP2003563518A patent/JP2005522422A/ja active Pending
- 2003-01-29 AT AT03702813T patent/ATE326985T1/de not_active IP Right Cessation
- 2003-01-29 NZ NZ534598A patent/NZ534598A/en not_active IP Right Cessation
- 2003-01-29 BR BR0307518-4A patent/BR0307518A/pt not_active IP Right Cessation
- 2003-01-29 CA CA002474710A patent/CA2474710A1/en not_active Abandoned
- 2003-01-29 AU AU2003205930A patent/AU2003205930B2/en not_active Ceased
- 2003-01-29 DE DE60305438T patent/DE60305438T2/de not_active Expired - Lifetime
- 2003-01-29 EP EP03702813A patent/EP1469886B8/en not_active Expired - Lifetime
- 2003-01-29 CN CNA038031442A patent/CN1625414A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04007328A (es) | 2005-07-05 |
| WO2003063824A3 (en) | 2004-06-17 |
| WO2003063824A2 (en) | 2003-08-07 |
| NZ534598A (en) | 2004-11-26 |
| CA2474710A1 (en) | 2003-08-07 |
| ATE326985T1 (de) | 2006-06-15 |
| AU2003205930B2 (en) | 2007-08-16 |
| EP1469886B8 (en) | 2008-01-09 |
| DE60305438D1 (de) | 2006-06-29 |
| BR0307518A (pt) | 2004-12-28 |
| EP1469886A2 (en) | 2004-10-27 |
| EP1469886B1 (en) | 2006-05-24 |
| US20050239746A1 (en) | 2005-10-27 |
| CN1625414A (zh) | 2005-06-08 |
| JP2005522422A (ja) | 2005-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69819721T2 (de) | Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden | |
| DE69130165T2 (de) | Cyclodextrinderivate mit erhöhter wasserlöslichkeit sowie deren verwendung | |
| DE69727218T2 (de) | Einschlusskomplexe von aryl-heterozyklischen salzen | |
| DE69531699T2 (de) | Cyclodextrinderivate und verfahren zu deren herstellung | |
| DE69331900T2 (de) | Cyclodextrinderivate mit erhöhter wasserlösichkeit und deren verwendung | |
| EP0684839B1 (de) | Verfahren zur herstellung kolloidaler wässriger lösungen schwer löslicher wirkstoffe | |
| DE60114249T2 (de) | Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure | |
| DE60011149T2 (de) | Klare wässrige anästhesierende zusammensetzung | |
| EP1469886B1 (en) | Lyophilized pharmaceutical composition of propofol | |
| DE69431476T2 (de) | Einschlusskomplexe von taxol oder taxotere oder taxus-extrakten und cyclodextrinen, ihre herstellung und ihre verwendung | |
| DE69518070T2 (de) | Mehrfachkomponenten-inklusionskomplexe enthaltend einen sauren arzneistoff, ein zyklodextrin und eine base | |
| DE69730902T2 (de) | Verfahren zur Selektion eines Salzes zur Herstellung eines Inklusionskomplexes | |
| AU2003205930A1 (en) | Pharmaceutical composition | |
| US6077871A (en) | Droloxifene pharmaceutical compositions | |
| WO1996032135A1 (en) | Pharmaceutical composition | |
| EP2484350B1 (de) | Pharmazeutische Zubereitung, enthaltend einen Komplex eines Propofolsalzes mit einem Cyclodextrin | |
| EP0490193A1 (de) | Komplexe des aktiven Enantiomers des Ibuprofens mit Cyclodextrin | |
| DE60305813T2 (de) | Stabile Oxazaphosphorin-2-Mercaptoethansulphonat Formulierungen | |
| DE69634446T2 (de) | Selektive alkylierung von cyclodextrinen mit minimaler effektiver basizität | |
| EP3360539A1 (de) | Pharmazeutische formulierung | |
| DE3782480T2 (de) | Gefriergetrocknete arzneimittel mit phenylchinolincarbonsaeuren. | |
| CH647677A5 (de) | 4'-(acridinylamino)-methansulfon-anisidid enthaltende pharmazeutische zusammensetzung. | |
| DE60020939T2 (de) | Salze von pharmakologisch aktiven peptiden mit verzögerter wirkstofffreigabe und deren herstellung | |
| EP1023075A1 (de) | Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte | |
| DE202024102879U1 (de) | Eine Zusammensetzung zur Behandlung von dreifach negativem Brustkrebs (TNBC) und eine Vorrichtung zu deren Synthese |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8381 | Inventor (new situation) |
Inventor name: PENKLER, LAWRENCE, JOHN, ., VERSTORBEN, ZA |